GE HealthCare raises 2026 outlook after positive Q3
GE HealthCare reported Q3 revenue of $5.5bn, with 7.2% YoY growth, raising its 2026 earnings outlook to $4.95-$5.05 per share. The company's stock opened at $76, up 7% from $71.11. Pharmaceutical diagnostics (PDx) saw the highest growth at 13% YoY, driven by the acquisition of SOFIE Biosciences for $945m, which is expected to enhance radiopharmaceutical offerings.
How this was made
The 30-second read
Why it matters
The earnings beat and raised guidance are likely to sustain the recent price rally and attract further buying interest.
Market read
Primary earnings and guidance news for a large‑cap healthcare company, with immediate price impact.
What to watch
Potential regulatory scrutiny of the SOFIE deal and competitive tension with Lantheus.
Background
GE HealthCare reported Q3 results ahead of market open, highlighting revenue growth across segments and announcing a $945m acquisition of SOFIE Biosciences.
Ticker impact
Q3 earnings released with $5.5bn revenue and raised 2026 EPS guidance to $4.95‑$5.05, stock opened up ~7% pre‑market.
likely upward pressure as investors price in higher earnings outlook
The earnings beat and guidance lift are fresh primary disclosures for a large‑cap, prompting a notable pre‑market rally.
Market effects
Strong PDx growth and acquisition may boost the broader medical‑device and radiopharma sectors.
U.S. healthcare equities could see modest gains.
Limited to healthcare investors; no broad macro effect.
Counterpoint
If the acquisition integration risks materialize, the stock could face downside despite the guidance lift.
Key entities
- companyGE HealthCare
Medical‑device and diagnostics business, ticker GEHC.
- companySOFIE Biosciences
Contract manufacturing organisation acquired for $945m.
